Trial Profile

A Phase 2 proof-of-concept development program of DGX-001 targeting mild cognitive impairment due to Alzheimer's Disease and Parkinson's Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2023 New trial record
26 Jul 2023 According to a Viage Therapeutics Media Release, the company is excited to make first-in-class oral drug candidate DGX-001 available to patients after initiation of the Phase 2 clinical program and in parallel discuss steps to file an investigational new drug application with the FDA.
26 Jul 2023 According to a Viage Therapeutics Media Release, results from phase 1 DGX-001 study support the initiation of a Phase 2 development program targeting mild cognitive impairment in multiple indications including Alzheimer's Disease (AD), and Parkinson's Disease (PD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com